Record growth for life science tech firm as MES adoption increases globally
Zenith Technologies surpasses the €20 million milestone for sales of its manufacturing execution system (MES) services.
Zenith Technologies provides MES and data historian deployment and support services to pharmaceutical and medical device manufacturers globally. The company has seen sales for this part of the business grow significantly over the last 5 years, with an average of over 35% year on year growth.
Commenting on the growth trend, James O’Brien, global MES business unit lead at Zenith Technologies, said: “MES has been the fastest growing segment of our offering and now represents almost a third of our business. Factors such as a greater regulatory focus on data integrity and customer demand for improved production performance have led to growing use of MES solutions within the pharmaceutical, biotech and medical device industries, which have traditionally been slow to adopt new technologies.
“The UK in particular is quickly becoming an MES centre of excellence, with MES sales representing 70% of our business in this market. Similarly, the US & Asia markets offer huge growth potential as the adoption of MES within the life science industry continues to grow across the globe.”
Zenith Technologies now works with nine of the top 10 pharmaceutical companies globally and during 2016 its team of engineers grew by almost 40% to over 700 employees.
To strengthen its ability to support customers in Europe, the US and Asia and accelerate further growth, the company has recently formed a number of strategic partnerships with MES technology providers, including Werum IT Solutions , AspenTech and LZ Lifescience. This will enable Zenith to support customers worldwide with on-site implementations of MES solutions designed to improve productivity, meet regulatory requirements during life science manufacturing and ultimately deliver vital medicines to patients as efficiently as possible.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance